CF PT202
Alternative Names: CF-PT202Latest Information Update: 10 Mar 2024
At a glance
- Originator Porosome Therapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cystic fibrosis
Most Recent Events
- 27 Feb 2024 Preclinical trials in Cystic fibrosis in USA (unspecified route)